Salarius Pharmaceuticals Files 8-K
Ticker: DCOY · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1615219
Sentiment: neutral
Topics: corporate-filing, disclosure, financials
TL;DR
Salarius Pharma filed an 8-K on 12/19/25 covering shareholder votes and financials.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on December 19, 2025, reporting on the submission of matters to a vote of security holders, Regulation FD disclosure, and financial statements/exhibits. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX.
Why It Matters
This filing indicates that Salarius Pharmaceuticals is engaging in corporate actions requiring shareholder votes and is providing necessary disclosures and financial updates.
Risk Assessment
Risk Level: low — This is a routine corporate filing and does not contain information suggesting immediate significant risk.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former company name
- December 19, 2025 (date) — Date of earliest event reported
- Houston, TX (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What is the nature of the Regulation FD disclosure?
The filing lists 'Regulation FD Disclosure' as an item, but the content of this disclosure is not detailed in the provided text.
What financial statements and exhibits are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific documents are not listed in the excerpt.
When did Salarius Pharmaceuticals change its name from Flex Pharma, Inc.?
The date of the name change from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc. was July 30, 2014.
What is the principal executive office address for Salarius Pharmaceuticals?
The principal executive offices are located at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
Filing Stats: 746 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-12-19 16:31:01
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20251219.htm (8-K) — 32KB
- slrx-pressreleasex2025annu.htm (EX-99.1) — 14KB
- 0001615219-25-000197.txt ( ) — 162KB
- flks-20251219.xsd (EX-101.SCH) — 2KB
- flks-20251219_lab.xml (EX-101.LAB) — 21KB
- flks-20251219_pre.xml (EX-101.PRE) — 12KB
- flks-20251219_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Pres s Release issued by Salarius Pharmaceuticals, Inc. dated December 19, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: December 19, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Executive Vice President & Chief Financial Officer